Prostate volume before and after permanent prostate brachytherapy in patients receiving neoadjuvant androgen suppression

Cancer Journal

Volumn 10, Issue 6, 2004, Pages 343-348

  Solhjem, Matthew C ^a,b   Davis, Brian J ^a,b,c   Pisansky, Thomas M ^a,b   Wilson, Torrence M ^a,b   Mynderse, Lance A ^a,b   Hillman, David W ^a,b   Herman, Michael G ^a,b   King, Bernard F ^a,c  

^a Mayo Clinic College of Medicine ^*

^b Mayo Clinic   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Brachytherapy; Neoadjuvant hormonal therapy; Prostate cancer; Prostate volume

Indexed keywords

ANDROGEN; HORMONE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GOSERELIN; LEUPRORELIN;

ADJUVANT THERAPY; ARTICLE; BRACHYTHERAPY; CONTROLLED STUDY; EDEMA; HORMONAL REGULATION; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; AGED; COMPARATIVE STUDY; ECHOGRAPHY; MALE; MIDDLE AGED; PROSTATE TUMOR; RADIOGRAPHY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; GOSERELIN; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSTATE; PROSTATIC NEOPLASMS;

EID: 15744390321     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200411000-00003     Document Type: Article

References (22)

1. Lee WR. The role of androgen deprivation lherapy combined with prostate brachytherapy. Urology 2002;60[suppl 3A]:39-44.
2. Gleave ME, Goldenberg SL, Chin JL et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001;166:500-507.
3. Henderson A, Langley SEM, Laing RW. Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study. Clin Oncol 2003;15: 318-321.
4. Shearer RJ, Davies JH, Gelister JS et al. Hormonal cytoreduction and radiotherapy for carcinoma of the prostate. Br J Urol 1992; 69:521-524.
5. Zelefsky MG, Leibel SA, Burman CM et al. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 1994;29:755-761.
6. Whittington R, Broderick GA, Arger P et al. The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1999;44: 1107-1110.
7. Kucway R, Vicini H, Huang R et al. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol 2002;167:2443-2447.
8. Stone NN, Clejan SJ. Response of prostate volume, prostate-specific antigen, and testosterone to flutamide in men with benign prostatic hyperplasia. J Androl 1991;12:376-380.
9. Kang SK, Chou RH, Dodge RK et al. Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading method. Int J Radiat Oncol Biol Phys 2001;50:937-945.
10. Sanghani MV, Schultz D, Tempany CM et al. Quantifying the change in endorectal magnetic resonance imaging-defined tumor volume during neoadjuvant androgen suppression therapy in patients with prostate cancer. Urology 2003;62:487-491.
11. Waterman FM, Yue N, Corn BW et al. Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on postimplantation dosimetry: an analysis based on serial CT acquisition. Int J Radiat Oncol Biol Phys 1998;41:1069-1077.
12. Speight JL, Shinohara K, Pickett B et al. Prostate volume change after radioactive seed implantation: possible benefit of improved dose volume histogram with perioperative steroid. Int J Radiat Oncol Biol Phys 2000;48:1461-1467.
13. Grado GL, Larson TR, Balch CS et al. Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Int J Radiat Oncol Biol Phys 1998;42:289-298.
14. Tong S, Downey DB, Cardinal HN et al. A three-dimensional ultrasound prostate imaging system. Ultrasound Med Biol 1996; 22:735-746.
15. Elliot TL, Downey DB, Tong S et al. Accuracy of prostate volume measurements in vitro using three-dimensional ultrasound. Acad Radiol 1996;3:401-406.
16. Sech S, Montoya J, Girman CJ et al. Interexaminer reliability of transrectal ultrasound for estimating prostate volume. J Urol 2001; 166:125-129.
17. Solhjem MC, Davis BJ, Pisansky TM et al. Prostate volume measurement by transrectal ultrasound and computed tomography before and after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2004;60:767-776.
18. Smith S, Wallner K, Merrick G et al. Interpretation of pre- versus post-implant TRUS images. Med Phys 2003;30:920-924.
19. Dubois DF, Prestidge BR, Hotchkiss LA et al. Intraobserver and interobserver variability of MR imaging- and CT-derived prostate volumes after transperineal interstitial permanent prostate brachytherapy. Radiology 1998;207:785-789.
20. Lee WR, Roach M, Michalski J et al. Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy. Int J Radiat Oncol Biol Phys 2002;54:457-461.
21. Al-Qaisieh B, Ash D, Bottomley AM et al. Impact of prostate volume evaluation by different observers on CT-based post-implant dosimetry. Radiat Oncol 2002;62:267-273.
22. Nag S, Beyer D, Friedland J et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999;44: 789-799.